Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today further details of the options that it has as part of the agreement to jointly develop and commercialize its investigational next generation Alzheimer's disease (AD) treatment candidates E2609, a BACE inhibitor, and BAN2401, an anti-amyloid beta (A Beta) protofibril
antibody, with Biogen Idec (Headquarters: Massachusetts, the United States, CEO: George A.
Four keratin helices twist around each other to form a protofibril
In addition, AEF appears to act as a protofibril
or focus of [Beta]-sheeting (the "nidus" theory).
Assessing the stability of Alzheimer's amyloid protofibrils
using molecular dynamics.
This is added to the continuing development of novel monoclonal antibody BAN2401, also a disease modifying treatment for Alzheimer's Disease targeting amyloid beta protofibrils
This binding leads to the formation of a half-staggered bimolecular array of fibrin molecules, and these protofibrils
subsequently condense both longitudinally and laterally to form the clot matrix (3).
As the process continues, these oligomers grow larger, becoming increasingly insoluble entities called protofibrils
Aiming to develop next-generation Alzheimer's disease treatments, Eisai is also pursuing the development of the novel monoclonal antibody BAN2401 targeting amyloid beta protofibrils
, and other compounds in addition to E2609, as it seeks to make further contributions to address the diversified needs of, and increase the benefits provided to, Alzheimer's disease patients and their families.
Aiming to develop next-generation Alzheimer's disease treatments, Eisai is also pursuing the development of the novel monoclonal antibody BAN2401 targeting for Abeta protofibrils
and other compounds in addition to E2609 as it seeks to make further contributions to address the diversified needs of, and increase the benefits provided to, Alzheimer's disease patients and their families.
, pores, fibrils, and netirodegeneration: separating the responsible protein aggregates from the innocent bystanders.
At present, we lack sufficient experimental evidence to make claims about differences in the detection of oligomers, protofibrils
, or small aggregates by these mAbs.
BAN2401 is the first monoclonal antibody to selectively bind, neutralize and eliminate soluble protofibrils
, the toxic amyloid-beta aggregates thought to cause Alzheimer's disease.